Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.43 |
| ▸ | TACR3 | P29371 | 4/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16784716 | 0.92 | SLC16A3 (0.36) | DHODHBCL9CTNNB1SLC16A3APP | |
| SCHEMBL13065614 | 0.92 | BCL9 (0.40) | DHODHHPSEBCL9CTNNB1SLC16A3 | |
| SCHEMBL16784718 | 0.92 | MAPT (0.41) | DHODHSLC16A3 | |
| SCHEMBL13065624 | 0.91 | DHODH (0.42) | DHODHTACR3ANO1SLC16A3 | |
| SCHEMBL13065592 | 0.89 | SLC16A3 (0.34) | DHODHSLC16A3 | |
| SCHEMBL16784714 | 0.86 | GPR35 (0.41) | DHODHCFTR | |
| SCHEMBL13065741 | 0.85 | DHODH (0.47) | DHODHTACR3BCL9CTNNB1 | |
| SCHEMBL13065604 | 0.84 | MEN1 (0.41) | DHODHBCL9CTNNB1SLC16A3 | |
| SCHEMBL13065593 | 0.84 | MEN1 (0.41) | DHODHSLC16A3 | |
| SCHEMBL13065602 | 0.84 | SCP2 (0.44) | SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9052324-B2 | Compounds and assays for controlling Wnt activity | ENZO BIOCHEM, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20120322717-A9 | Compounds and assays for controlling Wnt activity | ENZO BIOCHEM, INC. | 2012-12-20 | — | — | US | disclosed |
| US-20100298200-A1 | Compounds and assays for controlling Wnt activity | LIU DAKAI | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322717-A9 | Compounds and assays for controlling Wnt activity | WNT1, WNT3A, WNT3 | DHODH 3278/4885TACR3 3559/4885HPSE 1172/4885 |
| US-20100298200-A1 | Compounds and assays for controlling Wnt activity | WNT1, WNT3A, WNT3 | DHODH 3278/4885TACR3 3559/4885HPSE 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.